A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants

Inclusion Criteria: * Participant in general good health * Seeking improvement/correction of mid-face volume * Participant has overall mid-face severity of Moderate (3), Significant (4), or Severe (5) on the 6-point photonumeric MFVDS as assessed by the EI * Participant capable of giving signed informed consent Exclusion Criteria: * Has experienced trauma to the mid-face within 6 months before enrollment or has residual deficiencies, deformities, or scarring. * Conditions that could interfere with device effectiveness such as current cutaneous or mucosal inflammatory or infectious processes (eg, herpes), rosacea, abscess, an unhealed wound, active acne, or a cancerous or precancerous lesion in the mid-face * History of keloid scar formation, hypertrophic scarring, and/or post inflammatory hyperpigmentation * History of pigmentation disorders or current pigmentation disorder in the face * A history of facial surgeries in the mid-face * Received fat injection or permanent implants (eg, polymethylmethacrylate, silicone, polytetrafluoroethylene) anywhere in the face, or is planning to be implanted with any of these products at any time during the study * Received semipermanent soft-tissue filler treatment (eg, calcium hydroxyapatite, poly-L-lactic acid) in the mid-face within 36 months before enrollment, or is planning to be implanted with any of these products at any time during the study * Temporary soft tissue filler injections in the mid-face within 24 months before enrollment * Received botulinum toxin treatment to the midface within 6 months before enrollment, or is planning to undergo any such treatment during the study * Received mesotherapy or cosmetic facial procedures in the mid-face within 6 months before enrollment, or is planning to undergo any such treatment during the study * Any over-the-counter or prescription oral or topical, anti-wrinkle products for the mid-face within 30 days before enrollment (participants who have been on a regimen of such products for at least 30 days are eligible for the study if they intend to continue their regimen throughout the study) * Is on a prescribed regimen of anti-coagulation therapy (eg, warfarin, clopidogrel) * Tattoos, piercings, hair, or scars that would interfere with visualization of the cheek area for the effectiveness assessments * Pregnant, nursing, or planning a pregnancy